Evidence map›Paper›PMID 40055292›Full record

ArticleMolecular neurobiology2025

Apolipoprotein E ε4-Specific Relationship Between Serum Olfactomedin 4 and Alzheimer's Disease.

Chunxiao Wei, Guimei Zhang, Xiaoshu Fu, Meng Zhao, Weijie Zhai, Yanxin Shen, Li Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Robust Serum Proteomic Signature of the E2 Allele of Apolipoprotein E.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chunxiao WeiDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Guimei ZhangDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Xiaoshu FuDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Meng ZhaoDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Weijie ZhaiDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Yanxin ShenDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Li SunDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China. sunli99@jlu.edu.cn.

Funding

Doctor of excellence program (DEP), The First Hospital of Jilin University JDYY-DEP-2022015General Program of the National Natural Science Foundation of China 82071442Jilin Provincial Department of Finance JLSWSRCZX2021-004Major Chronic Disease Program of the Ministry of Science and Technology of China 2018YFC1312301STI2030-Major Projects 2021ZD0201802Youth Development Fund, The First Hospital of Jilin University JDYY14202338
6 · The paper itself

Abstract

Olfactomedin 4 (OLFM4) plays important roles in inflammation, immune regulation, apoptosis, and neurodevelopment. This study aimed to investigate the correlation of serum OLFM4 with Alzheimer's disease (AD) and its clinical phenotype in different apolipoprotein E (APOE) ε4 status. Serum OLFM4 levels were measured in 122 AD patients and 113 healthy controls (HC). Correlations between OLFM4 levels and cognitive function and brain volume were analyzed in the context of APOE ε4 status. Multivariate logistic regression modeling was used to assess the contribution of high OLFM4 levels and APOE ε4 status to the risk of AD. It turns out that serum OLFM4 levels were significantly higher in patients with AD than in HC and were associated with APOE ε4 status but not sex. Serum OLFM4 levels showed a dose-response relationship with cognitive function and were correlated with brain atrophy. The combination of high OLFM4 levels and APOE ε4 expression was a risk factor for AD (odds ratio = 5.440; p = 0.017). In conclusion, serum OLFM4 may be involved in the pathology of AD and holds promise as a potential biomarker of AD as well as a therapeutic target. And the effects of OLFM4 for AD may be mediated by APOE ε4.

Indexed as

Alzheimer DiseaseApolipoprotein E4Granulocyte Colony-Stimulating FactorAgedAtrophyBiomarkersBrainCase-Control StudiesCognitionFemaleHumansMaleMiddle AgedApolipoprotein E4BiomarkersGranulocyte Colony-Stimulating FactorOLFM4 protein, humanAlzheimer’s diseaseApolipoprotein EBrain volumeCognitive functionOlfactomedin 4

Identifiers

PMID40055292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.